Drug facts

Semaglutide and constipation

By David Chen·Editor·Reviewed August 2026

How common it was¹

Constipation sits fourth in the label’s table of reactions reported in 2% or more of participants, behind nausea, diarrhea and vomiting. The arm was 2,116 adults on semaglutide 2.4 mg against 1,261 on placebo.

The placebo column is doing real work here. Constipation is common in the general population and commoner still in people who are eating less, so nearly half the figure would have happened without the drug. That is still 13 percentage points of it that would not have.

Why there is no dose breakdown¹

A reader who has seen the equivalent page for tirzepatide will notice something missing. That label reports its reaction rates by dose; this one reports a single maintenance-dose arm, because the trials behind it titrated everyone to 2.4 mg. So there is no published rate for constipation at 0.5 mg or 1 mg, and any page offering one is not reading this label.

What the label does say is that gastrointestinal reactions arise mainly during dose escalation, which is the reason the four-week steps exist. That is a statement about timing, not about which dose is gentler.

Why the drug does this¹

Semaglutide slows gastric emptying — that is part of how it works, not a malfunction. Food stays in the stomach longer, the whole transit slows behind it, and less food going in means less bulk moving through. The same mechanism produces the fullness people are taking it for.

It is also why the same label carries a warning about general anesthesia and deep sedation: a stomach that empties slowly can still hold contents after a normal pre-operative fast.

When it is not just constipation¹

The label lists several serious gastrointestinal conditions among its warnings, and some of them can begin as symptoms that look like ordinary constipation — severe or persistent abdominal pain, or constipation that does not resolve. Nausea, by comparison, was reported by 44% and is expected; pain that is severe is not the same thing. The label’s description of acute pancreatitis begins with exactly that kind of pain.

Which of those applies to any particular person is not something a page can tell you. It is what a prescriber is for.

What this page is not

This reports what the approved label recorded, and it deliberately offers no remedies — that is your prescriber’s decision, not this site’s. Nor are these figures measurements of a compounded vial: no compounded preparation has run a trial of its own. See the full table.